A5014357212- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Multiple Myeloma Research and Treatments
- Chemical Synthesis and Analysis
- Nanoparticle-Based Drug Delivery
- Nanoplatforms for cancer theranostics
- Mass Spectrometry Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Medical Imaging and Pathology Studies
- Medical Imaging Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Radiation Therapy and Dosimetry
- Peptidase Inhibition and Analysis
- Electron and X-Ray Spectroscopy Techniques
- Computational Drug Discovery Methods
- Pharmacological Receptor Mechanisms and Effects
- Nuclear Physics and Applications
- Neuropeptides and Animal Physiology
- Radiation Effects and Dosimetry
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- SARS-CoV-2 and COVID-19 Research
- Receptor Mechanisms and Signaling
- Synthesis of β-Lactam Compounds
University of California, San Francisco
2022-2025
University of California System
2025
University of Delhi
2020
Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression developed an antibody-drug conjugate immunoPET agent based on YS5 antibody, which targets a tumor-selective epitope. Here, we present preparation, preclinical efficacy, toxicity evaluation [225Ac]DOTA-YS5, radioimmunotherapy antibody.
Ac, a long-lived α-emitter with half-life of 9.92 days, has garnered significant attention as therapeutic radionuclide when coupled monoclonal antibodies and other targeting vectors. Nevertheless, its clinical utility been hampered by potential off-target toxicity, lack optimized chelators for
Although the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) is wreaking havoc and resulting in mortality morbidity across planet, novel treatments are urgently needed. Drug repurposing offers an innovative approach this context. We report here new findings on silico potential of several antimalarial drugs for against COVID-19. conducted analyses docking compounds two SARS-CoV-2-specific targets: (1) receptor binding domain spike...
<sup>225</sup>Ac-targeted α-radiotherapy is a promising approach to treating malignancies, including prostate cancer. However, α-emitting isotopes are difficult image because of low administered activities and fraction suitable γ-emissions. The in vivo generator <sup>134</sup>Ce/<sup>134</sup>La has been proposed as potential PET imaging surrogate for the therapeutic nuclides <sup>225</sup>Ac <sup>227</sup>Th. In this report, we detail efficient radiolabeling methods using...
The tumor uptake of large non-targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved 4-arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate-specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA-targeted delivery therapeutic efficacy, StarPEG nanodrugs with/without three copies PSMA-targeting ligands, ACUPA, are...
Targeted nanoparticles have been extensively explored for their ability to deliver payload a selective cell population while reducing off-target side effects. The design of actively targeted requires the grafting ligand that specifically binds highly expressed receptor on surface population. Optimizing interactions between targeting and can maximize cellular uptake subsequently improve activity. Here, we evaluated how density presentation ligands dictate nanoparticles. To do so, used...
Abstract Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as overexpressed therapeutic target in multiple developed the antibody YS5, which targets cancer-specific epitope on this protein. We further CD46-targeting PET probe [89Zr]Zr-DFO-YS5 [225Ac]Ac-DOTA-YS5 radiopharmaceutical therapy of prostate cancer. These prior studies suggested feasibility antigen theranostic myeloma. Herein,...
<p>Supplementary Figure S23. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of 89Zr labeled nanocarriers nude mice inoculated with 22rv1 cells via intracardiac injection at 72 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S7. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 72 96 h following administration of 150-170 μCi 89Zr labeled nanocarriers in nude mice bearing LTL-610 patient derived xenograft (PDX) tumors over left flanks.</p>
<p>Supplementary Figure S11. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing LTL-610 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S4. Coronal μPET/CT fusion and MIP images obtained at 18 h, 48 72 96 h following administration of 150-170 μCi 89Zr labeled nanocarriers in nude mice bearing 22rv1 subcutaneous tumors over left flanks.</p>
<p>Supplementary Figure S22. BLI of all mice in the cohort inoculated with 22rv1-Luc cells left kidney capsule that demonstrate prominent signal metastatic tumors at neck and thigh region on day 89Zr labeled nanocarrier injection.</p>
<p>Supplementary Figure S8. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing 22rv1 subcutaneous tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S17. Immunofluorescence CD31 staining of the respective tumor tissue sections using rat anti-mouse antibody indicating vascular development in different phenotypes.</p>
<p>Supplementary Figure S18. BLI of all mice in the cohort inoculated with 22rv1-Luc cells left kidney capsule that demonstrate prominent signal metastatic tumors at neck and thigh region on day [89Zr]PEG-DFB1-TLZ3 injection. Black arrows indicate presence tumors.</p>
<p>Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)</p>
<p>Supplementary Figure S15. Autoradiographic images of PDX LTL-610 tumor sections from day 1 to 3 post injection 89Zr labeled nanocarriers. H&E staining the respective timepoints are not available.</p>
<p>Supplementary Figure S13. Autoradiographic images and H&E staining of subcutaneous CT26 tumor sections from day 1 to 4 post injection 89Zr labeled nanocarriers. *Indicate the presence necrosis.</p>
<p>Supplementary Figure S3. Ex vivo tumor biodistribution, (a) %ID per gram and (b) organ of nude mice bearing different models including prostate cancer (22rv1, PC3, DU145), colorectal (CT26), pancreatic (BxPC3) at 24h 72 h post-injection [89Zr]PEG-DFB1-TLZ3. The respective (c) uptakes, (d) to muscle ratio, (e) blood ratio the same mice. (n = 4, mean ± SD) (f) Autoradiographic images sections from mouse model preclinical xenograft 72h [89Zr]PEG-DFB1-TLZ3.</p>